|Bid||161.02 x 900|
|Ask||165.22 x 800|
|Day's Range||161.01 - 163.20|
|52 Week Range||114.27 - 197.00|
|Beta (3Y Monthly)||1.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||2.96 (1.82%)|
|1y Target Est||179.79|
Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
- Dividend to be Paid on September 13, 2019 - - Record Date of August 13, 2019 - DUBLIN , July 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared ...
THOUSAND OAKS, Calif., July 18, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).
Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman. According to the order unsealed July 16, 2019, by Chief Judge William E. Smith of the District of Rhode Island, damages to the class are on the order of $625.2 million – $1.9 billion after automatic trebling under antitrust rules. Trial in the class-action lawsuit is set for January 6, 2020, in Providence, Rhode Island.
DUBLIN, July 17, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost SR if approved would be the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Bernstein analyst Ronny Gal says the spread between the current stock price and AbbVie’s offer is fair and it is time to take the foot off the gas.
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
NEW YORK, July 12, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating the following companies: Del Frisco’s Restaurant Group, Inc. (NASDAQ: DFRG)The.
J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
A federal judge dealing a blow to the Trump Administration by striking down a new rule that would have forced pharma companies to include the wholesale prices of their drugs in TV ads. Yahoo Finance's Seana Smith and Alexis Keenan discuss.